Zymeworks Inc. Common Stock

2026-05-08 12:10:11

Zymeworks Inc. (NASDAQ: ZYME) held its Q1 2026 earnings call, reporting an EPS miss of $-0.59 against an expectation of $-0.1. The company highlighted significant upcoming milestones, including the PDUFA date for zanatumab in first-line GEA, anticipating milestone payments from Jazz and BeiGene, and substantial royalty revenues upon potential commercialization. They also discussed progress on their pan-RAS ADC platform, encouraging Phase 1 data for ZW191 in ovarian and endometrial cancers, and updates on ZW251, along with a disciplined capital allocation strategy including share repurchases.

2026-05-07 20:09:21

Zymeworks reported a Q1 2026 net loss of $44.2 million, wider than the previous year, with collaboration revenue falling significantly to $2.4 million due to fewer milestone payments. However, the company boosted its cash, cash equivalents, and marketable securities to over $400 million by monetizing 30% of future Ziihera royalties for $250 million through a non-recourse term loan. Zymeworks also continued its share repurchase program, buying back 3.2 million shares for $76.6 million in the quarter, while advancing its pipeline and awaiting regulatory milestones for Ziihera, including priority FDA review for HER2-positive gastroesophageal cancers.

2026-03-06 20:10:42

Zymeworks Inc. reported its financial results for the fourth quarter and full year 2025, highlighting a strategic shift towards predictable revenue streams and disciplined capital allocation. The company announced significant progress with its partnered programs, including regulatory submissions and approvals for Ziihera, and reported a substantial increase in total revenue for 2025 alongside a reduced net loss, supported by a $250.0 million non-recourse royalty-backed note financing. Zymeworks also provided an update on its share repurchase program and financial outlook, projecting its existing cash alongside anticipated milestones and financing to fund operations beyond 2028.

2026-03-06 16:39:06

Zymeworks reported a significant financial improvement in 2025, with total revenue rising 39% to $106.0 million and its net loss narrowing by 34% to $81.1 million. The company ended the year with strong liquidity, holding $270.6 million in cash and short-term investments, further bolstered by a new $250.0 million royalty-backed note from Royalty Pharma. This strategic financing and disciplined expense management are expected to extend Zymeworks' cash runway beyond 2028, supporting ongoing share repurchases and potential acquisitions.

2026-03-03 12:53:12

Zymeworks Inc. discussed its Q4 2025 earnings and provided updates on its clinical programs and strategic financing. Key highlights include positive Phase III results for zanidatumab in HER2-positive GEA, a new $250 million royalty-backed note financing with Royalty Pharma to fund share repurchases and potential acquisitions, and progress in other clinical trials such as ZW251 and ZW191. The company reiterated its commitment to disciplined capital allocation and expansion of its royalty-generating asset portfolio.

2026-03-03 07:10:25

Zymeworks announced its fourth-quarter and full-year 2025 financial results, highlighting a 39% increase in total revenue to $106.0 million and a 34% reduction in net loss to $81.1 million compared to 2024. The company also provided a corporate update, including a $250.0 million royalty-backed note financing with Royalty Pharma, $62.5 million utilized for share repurchases, and significant progress with its partnered programs Ziihera and pasritamig, anticipating regulatory approvals and milestone payments. Zymeworks reported $270.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, projecting a cash runway beyond 2028.